Amgen Reports Results of Otezla (apremilast) in P-III ADVANCE Study for Mild-To-Moderate Plaque Psoriasis
Amgen Reports Results of Otezla (apremilast) in P-III ADVANCE Study for Mild-To-Moderate Plaque Psoriasis
Shots: Shots:
- The P-III ADVANCE study involves assessing of Otezla (apremilast, 30mg, bid for 16wks.) vs PBO in 595 patients in a ratio (1:1) with mild-to-moderate plaque psoriasis. Later, patients will receive Otezla during an open-label extension phase @32wks.
- The P-III ADVANCE study results: @16wks., improvement in its 1EPs of sPGA score; achieve 2EPs i.e, 75% improvement in BSA, change in PASI score
- Otezla is a selective PDE4 inhibitor, inhibiting the production of TNF-alpha from human rheumatoid synovial cells and is an approved therapy for mod. to sev. plaque psoriasis who are candidates for phototherapy or systemic therapy, for active PsA and for with oral ulcers associated with Behçet’s Disease
Click here to read full press release/ article | Ref: Amgen | Image: StraitTimes